Inactive Instrument

News Respirerx Pharmaceuticals Inc Other OTC

Equities

US2205243007

End-of-day quote Other OTC Other stock markets
- ^USD	-

Apr. 10	RespireRx Pharmaceuticals Inc. announced that it has received $0.1 million in funding	CI
Mar. 20	RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RespireRx Pharmaceuticals Inc. announced that it has received $0.1 million in funding	Apr. 09	CI
RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury	Mar. 20	AQ
RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury	Mar. 20	CI
RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine	Feb. 13	AQ
RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for Their Non-Opioid Lead GABAkine	Feb. 13	CI
RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors	Jan. 22	AQ
RespireRx Pharmaceuticals Inc. Announces the Appointment of Dariusz Naziek to its Board of Directors	Jan. 22	CI
RespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient	Jan. 04	AQ
Respirerx Pharmaceuticals Inc. Announces the Publication of A Case Report in Which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient	Jan. 04	CI
RespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business Development	Dec. 11	AQ
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 17	CI
Today's Top OTC Stocks Watchlist (SWISF, EPAZ, ABQQ, RSPI)	23-10-13	AQ
RespireRx Pharmaceuticals Inc.’s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related Services	23-10-12	AQ
RespireRx Pharmaceuticals : SETTLEMENT AND EXCHANGE AGREEMENT - Form 8-K	23-10-02	PU
Attention Deficit Hyperactivity Disorder Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)	23-09-26	AQ
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-21	CI
CapitalGainsReport: Sub Penny Stocks Set To Soar: EPAZ, RSPI, TPTW, HGEN	23-08-10	AQ
RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating Company	23-08-09	AQ
RespireRx Pharmaceuticals : Cortex Pharmaceuticals, Inc. 2014 Equity, Equity-Linked and Equity Derivative Plan - Form 8-K	23-06-13	PU
RESPIRERX PHARMACEUTICALS INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	23-06-13	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Respirerx Pharmaceuticals Inc Other OTC

Equities

US2205243007

Summary

Filters